Makers of EZorb and Marvlix
 

EZorb®

 
 

Ann Intern Med. 2003 Jul 15;139(2):97-104

 

Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.

 

LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD. Women's Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-1002, PO Box 19024, Seattle, Washington 98109-1024, USA.

 

BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results.

 

OBJECTIVE: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density.

 

DESIGN: Prospective study.

 

SETTING: Women's Health Initiative Observational Study conducted in 40 clinical centers in the United States.

 

PARTICIPANTS: 93 716 postmenopausal women ages 50 to 79 years.

MEASUREMENTS: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use.

 

RESULTS: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivariate-adjusted hazard ratios for current statin use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors.

 

CONCLUSION: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.

 

 

 

Osteoporosis - Comparison of Treatment Options

Compare EZorb Calcium with Osteoporosis Prescription Drugs

Bone and Joint Overview

Clinical Studies

The Importance of Collagen for Bone and Joint Health

Causes of Osteoarthritis

Treatment of Osteoarthritis - Review of Various Options

Is Rheumatoid Arthritis (RA) Really an Autoimmune Disease?

Breaking the Vicious Circle of Fibromyalgia

Bone Spur - A Natural Approach

Do You Suffer from Heel Spurs?

Juvenile Rheumatoid Arthritis

Quick EZorb Calcium Osteoporosis Facts

 

Ready to order? Go directly to our online store, or call 1-800-395-5715. Open 24 hours a day, 7 days a week. You may also use the mail order form to mail us your order.

 

 

 

 

Copyright © 2017 Elixir Industry. All Rights Reserved.